Management ChangeMay 21, 2026, 04:24 PM
Genvor Appoints Donald Kalkofen as Chief Financial Officer
AI Summary
Genvor Inc. has appointed Donald Kalkofen as its new Chief Financial Officer, effective May 18, 2026. Mr. Kalkofen brings over 20 years of CFO experience, including a strong track record in initial public offerings and complex capital markets transactions across biotechnology and financial services. His compensation package includes monthly cash and deferred cash, along with stock options, with an amended agreement detailing payment terms and a future salary increase. This appointment is expected to support Genvor's dual-market growth strategy and potential future listing.
Key Highlights
- Genvor Inc. appointed Donald Kalkofen as Chief Financial Officer, effective May 18, 2026.
- Mr. Kalkofen brings over 20 years of CFO experience, including guiding companies through IPOs and capital markets transactions.
- He previously served as CFO for Alpha Cognition, Inc. and Protagonist Therapeutics Inc.
- Initial compensation includes $6,250 per month cash and $7,750 per month deferred cash.
- Mr. Kalkofen received 10-year stock options to purchase 575,000 shares of common stock.
- 425,000 options vest monthly over 12 months; 150,000 vest upon successful national securities exchange listing.
- An amended agreement sets an initial term of 12 months from May 21, 2026.
- Deferred compensation of $7,750/month is payable in a lump sum by December 31, 2026.
- Monthly cash compensation will increase to $14,000 from January 1, 2027.
Price Impact
More from GNVR